Previous close | 3.9483 |
Open | 3.8500 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 3.8150 - 3.8950 |
52-week range | 2.7333 - 7.3100 |
Volume | |
Avg. volume | 9,055 |
Market cap | 518,884 |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NANTES, France, November 21, 2023--OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has entered into a collaboration with GenDx (a Eurobio Scientific Company, a key player in the field of specialty in vitro diagnostics) to develop and validate a companion diagnostic (CDx) test to support the confirmatory pivotal Phase 3 clinical trial of Tedopi® cancer vaccine candidate in preparation in Non-Small Cell Lung Cancer (NSCLC) second line treatment. GenDx, o
NANTES, France, October 23, 2023--OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
NANTES, France, October 16, 2023--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).